PD-L1 is frequently upregulated by tumor cells as an adaptive mechanism to evade immune surveillance while increasing PD-1 expression on immune cells, leading to CD8+ T-cell exhaustion, impairing antitumor immune responses, and stimulating tumor progression [9]. Here, PDCD1 is linked to neoplasm.